Oct 30, 2026 · FDA target
INO-3107 FDA review target
PDUFA target action date
The FDA review concerns INO-3107 for recurrent respiratory papillomatosis. Watch for the agency's action and next steps.
Original source ↗Nasdaq
INO Research Hub
INOVIO PHARMACEUTICALS, INC.
Latest signal
8-K filed 2026-10-06
8-K
PennyIntel health score
7.2/10
Higher is healthier / lower risk. Constructive
What to watch next
Newest source: 8-K. Useful checks are financing terms, proxy votes, ownership changes, compliance notices, and material-event language.
Dates to watch
Upcoming catalysts
Showing the latest available coverage. No matching headlines from the past 48 hours were found.
News pulse
Latest related coverage
Coverage is quiet. Keep SEC filings, ownership changes, and discussion alerts active.
Inovio Pharmaceuticals (INO) Awarded $80.4M in Legal Case Amid Financial Challenges
On October 20, 2026, Inovio Pharmaceuticals Inc (ticker: INO) announced it has been awarded $80.4 million in a legal judgment against VGXI and GeneOne Life Scie
On October 20, 2026, Inovio
Contract/order
Premarket/momentum
INO Looks 490.5% Overvalued on GF Value™
On September 21, 2026, Inovio Pharmaceuticals Inc (NASDAQ: INO) saw a notable increase in its indicative borrow rate, rising by 2.89% and adding 0.58 points ami
On September 21, 2026, Inovio
Compliance
Inovio Pharmaceuticals, Inc. (INO) Presents at H.C. Wainwright 28th Annual Global Investment Conference Prepared Remarks Transcript
Inovio Pharmaceuticals, Inc. (INO) H.C.
Jacqueline Shea, President and CEO of
Inovio Pharmaceuticals, Inc. (INO) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
Inovio Pharmaceuticals, Inc. (INO) 12th Annual Cantor Fitzgerald Global Healthcare Conference September 9, 2026 3:20 PM EDTCompany ParticipantsJacqueline...
Inovio Pharmaceuticals, Inc. (INO) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
Inovio Stock: The Final Countdown To A Binary FDA Decision (NASDAQ:INO)
Inovio Pharmaceuticals is a single-asset, late-stage biotech, with value hinging on the October 30th PDUFA decision for INO-3107. Learn why INO stock is a hold.
I see Inovio Pharmaceutical[+154 characters]
Compliance
FDA/clinical
Inovio Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary
Moby summary of Inovio Pharmaceuticals, Inc.'s Q2 2026 earnings call
Inovio Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary
Earnings/results
Community pulse
INO trader notes
No trader notes yet for INO. Be first to add a filing note, catalyst watch, or risk warning.
Checking account...
Alert signals
Signals worth watching
Inovio Pharmaceuticals (INO) Awarded $80.4M in Legal Case Amid Financial Challenges
On October 20, 2026, Inovio Pharmaceuticals Inc (ticker: INO) announced it has been awarded $80.4 million in a legal judgment against VGXI and GeneOne Life Scie
8-K filed 2026-10-06
8-K
Dilution safety at 6/10
This is the weakest current PennyIntel check. Put alerts on financing, proxy, compliance, and ownership changes before treating the setup as clean.
SCHEDULE 13G/A · 2026-08-12
Beneficial ownership filing detected. Check who disclosed a meaningful position and whether it changed.
What should trigger a follow-up
Newest source: 8-K. Useful checks are financing terms, proxy votes, ownership changes, compliance notices, and material-event language.
Follow this ticker to track news, SEC changes, ownership activity, catalysts, risk moves, and active discussion in one place.
Filings worth checking
No recent split/proxy filing was flagged in the latest SEC feed. Start with the latest filings below for verified source context.